Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study

Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study

Abstract Background Pemafibrate, a selective PPARα modulator, has the beneficial effects on serum triglycerides (TGs) and very low density lipoprotein (VLDL), especially in patients with diabetes mellitus or metabolic syndrome. However, its effect on the low density lipoprotein cholesterol (LDL-C) l...

Full description

Bibliographic Details
Main Authors: Ichiro Komiya, Akira Yamamoto, Suguru Sunakawa, Tamio Wakugami
Format: Article
Language:English
Published: BMC 2021-02-01
Series:Lipids in Health and Disease
Subjects:
Low density lipoprotein cholesterol
Pemafibrate
Small
Dense LDL
Triglycerides
Type 2 daibetes
Online Access:https://doi.org/10.1186/s12944-021-01434-8

Internet

https://doi.org/10.1186/s12944-021-01434-8

Similar Items